Home The Word Brain	My Amedeo FAQ Privacy About
	Chinese Coaching Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.

Multiple Sclerosis

Free Subscription 05.01.2026 2 Ann Neurol 1 BMC Neurol 1 Can J Neurol Sci 1 J Neuroimmunol 4 J Neurol 2 J Neurol Sci 13 Mult Scler 2 Neurology 2 PLoS One

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Ann Neurol

1. SABATINO JJ JR, Cree BAC, Hauser SL
   Reply to "New Horizons for Multiple Sclerosis Therapy: 2025 and Beyond".
   Ann Neurol. 2025 Dec 24. doi: 10.1002/ana.78124.
   PubMed        
   
   
2. BIRNBAUM G
   New Horizons for Multiple Sclerosis Therapy: 2025 and Beyond.
   Ann Neurol. 2025 Dec 24. doi: 10.1002/ana.78121.
   PubMed        
   
   

   
   BMC Neurol

3. ALNAJASHI H, Almohammed HAJ, Morad AS, Bin Saddiq BW, et al
   Safety and efficacy of oral cladribine in relapsing multiple sclerosis: a systematic review and meta-analysis.
   BMC Neurol. 2025;25:510.
   PubMed         Abstract available
   
   

   
   Can J Neurol Sci

4. OZDEMIR O, Batuk IT, Fil Balkan A, Acar Ozen P, et al
   The Role of Central Vestibular Dysfunction in Cognitive and Physical Impairment in Ambulatory Multiple Sclerosis.
   Can J Neurol Sci. 2026 Jan 2:1-8. doi: 10.1017/cjn.2025.10502.
   PubMed         Abstract available
   
   

   
   J Neuroimmunol

5. BUNGANIC R, Revendova KZ, Hradilek P, Kusnierova P, et al
   Comparison of SIMOA and VEUS technologies for serum glial fibrillary acidic protein measurement.
   J Neuroimmunol. 2026;411:578825.
   PubMed         Abstract available
   
   

   
   J Neurol

6. SURCINELLI A, Massa I, Gentili N, Panzera I, et al
   Harmonized magnetic resonance imaging protocols for multiple sclerosis: HARMONY-MS, a pilot project.
   J Neurol. 2025;273:39.
   PubMed         Abstract available
   
   
7. RESTUCCIA G, Susinna C, Marafioti G, Rifici C, et al
   Serum and cerebrospinal fluid biomarkers as predictors of cognitive impairment in multiple sclerosis: a systematic review of longitudinal studies.
   J Neurol. 2025;273:36.
   PubMed         Abstract available
   
   
8. CHISARI CG, Lo Fermo S, Di Sapio A, Amato MP, et al
   Effectiveness of Rituximab in rElapsiNg Multiple SclErosis previously treated with hiGhly-Active Disease modifying thErapies (RENEGADE study).
   J Neurol. 2025;273:47.
   PubMed         Abstract available
   
   
9. YANG J, Li H, Zhang Y, Hu S, et al
   Correction: Effects of exercise on fatigue and quality of life in multiple sclerosis: a network meta-analysis and systematic review.
   J Neurol. 2025;273:51.
   PubMed        
   
   

   
   J Neurol Sci

10. JAKIMOVSKI D, Bergsland N, Marr K, Dwyer MG, et al
    Lower vascular cerebral flow and cerebral perfusion may be associated with impairment of the glymphatic system in multiple sclerosis: A cross-sectional DTI-ALPS MRI study.
    J Neurol Sci. 2025;480:125709.
    PubMed         Abstract available
    
    
11. TYAGI B, Toppo L, Biradar A
    Comment on "wearing-off symptoms persist in the majority of patients with multiple sclerosis after switching from natalizumab to ocrelizumab".
    J Neurol Sci. 2025;480:125705.
    PubMed        
    
    

    
    Mult Scler

12. RANUCCI D, Falco F, Nicolella V, Marra LA, et al
    Dysarthria assessment in multiple sclerosis patients.
    Mult Scler. 2026;32:134-143.
    PubMed         Abstract available
    
    
13. MOROZUMI T, Preziosa P, Meani A, Pagani E, et al
    Contribution of structural and functional MRI in predicting response to motor training in multiple sclerosis.
    Mult Scler. 2026;32:93-106.
    PubMed         Abstract available
    
    
14. LIZAK N, Sharmin S, Horakova D, Havrdova EK, et al
    Managing reactivation of multiple sclerosis during treatment with natalizumab.
    Mult Scler. 2026;32:121-133.
    PubMed         Abstract available
    
    
15. BORRELLI S, Guisset F, Farneti M, Stolting A, et al
    Dietary habits and advanced imaging/laboratory markers in multiple sclerosis: An exploratory cross-sectional study.
    Mult Scler. 2026;32:69-79.
    PubMed         Abstract available
    
    
16. CALABRESI PA, Giovannoni G, Hartung HP, Naismith RT, et al
    Safety and efficacy of opicinumab in participants with relapsing multiple sclerosis (AFFINITY Part 1): A randomized, controlled, phase 2 trial.
    Mult Scler. 2026;32:107-120.
    PubMed         Abstract available
    
    
17. MARRIE RA, Dobson R, Baranzini SE, Salvetti M, et al
    Toward a global research agenda for preventing multiple sclerosis.
    Mult Scler. 2025 Dec 26:13524585251398381. doi: 10.1177/13524585251398381.
    PubMed         Abstract available
    
    
18. BRIGGS F, Nyati A, Zweig S, Leung LJ, et al
    Allergic phenotypes and asthma in multiple sclerosis: Epidemiologic and genetic relationships.
    Mult Scler. 2025 Dec 27:13524585251398382. doi: 10.1177/13524585251398382.
    PubMed         Abstract available
    
    
19. BERNSTEIN HR, Grouza V, Gati JS, Morrow SA, et al
    Periventricular gradients in axonal and myelin microstructure are present in people with multiple sclerosis having low and high disability.
    Mult Scler. 2026;32:80-92.
    PubMed         Abstract available
    
    
20. KIM SH, Kang YR, Chung J, Joo M, et al
    Optimizing kappa free light chain index thresholds for multiple sclerosis (MS) diagnosis in low-MS prevalence regions: Insights from an Asian cohort.
    Mult Scler. 2025 Dec 27:13524585251399102. doi: 10.1177/13524585251399102.
    PubMed         Abstract available
    
    
21. ITO M, Masuda H, Morooka M, Sugiyama A, et al
    Gerstmann-Straussler-Scheinker disease mimicking primary progressive multiple sclerosis: A case with positive oligoclonal bands.
    Mult Scler. 2025 Dec 29:13524585251401053. doi: 10.1177/13524585251401053.
    PubMed         Abstract available
    
    
22. DE NAPOLI G, Gotti E, Baldovini C, Di Sciascio L, et al
    Cardiogenic shock after ocrelizumab infusion in relapsing-remitting multiple sclerosis.
    Mult Scler. 2025 Dec 31:13524585251407501. doi: 10.1177/13524585251407501.
    PubMed         Abstract available
    
    
23. RATZAN AS, Simani L, Dworkin JD, Buyukturkoglu K, et al
    Characterizing the extended language network in individuals with multiple sclerosis.
    Mult Scler. 2025 Dec 31:13524585251398451. doi: 10.1177/13524585251398451.
    PubMed         Abstract available
    
    
24. GUHA NIYOGI P, Sanjayan M, Ghosal R, Goldsmith J, et al
    Quantifying observable movement reserve in multiple sclerosis via upper diurnal activity quantiles.
    Mult Scler. 2026 Jan 1:13524585251398689. doi: 10.1177/13524585251398689.
    PubMed         Abstract available
    
    

    
    Neurology

25. LANGER-GOULD A, Li BH, Smith JB, Nielsen AS, et al
    Comparative Effectiveness of Rituximab Dosed Every 6 and 12 Months in Relapsing Multiple Sclerosis.
    Neurology. 2026;106:e214473.
    PubMed         Abstract available
    
    
26. MOCCIA M, Silbermann E
    Can Once-Yearly Rituximab Dosing Be "Enough" for Most People With Relapsing Multiple Sclerosis?
    Neurology. 2026;106:e214586.
    PubMed        
    
    

    
    PLoS One

27. CARDINI R, Gervasoni E, Germanotta M, Aprile IG, et al
    Consensus on recommended evaluation tools in multiple sclerosis (CORE-MS): A Delphi study protocol on balance and gait assessment.
    PLoS One. 2026;21:e0337440.
    PubMed         Abstract available
    
    
28. BUCHKA S, Havla J, On BI, Rehms R, et al
    Individual-level surrogacy of MRI lesions for disease severity in RRMS: Methods to quantify predictive power and their application to longitudinal data from recent trials.
    PLoS One. 2025;20:e0337893.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Multiple Sclerosis is free of charge.